{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:01:23Z","timestamp":1782853283861,"version":"3.54.5"},"reference-count":28,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-sa\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Background<\/jats:title>\n Obesity is a chronic disease associated with substantial morbidity and healthcare costs. In Japan, the Optimal Use Promotion Guidelines (OUG) impose restrictions on patient eligibility for semaglutide 2.4 mg and limit treatment duration. This study evaluated the cost-effectiveness of semaglutide 2.4 mg in Japan under retreatment assumptions informed by OUG requirements.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A Markov cohort model (Core Obesity Model) was used to evaluate lifetime clinical and economic outcomes from a Japanese public payer perspective. The Core Obesity Model assesses the associations between risk factors and the incidence of obesity-related complications. People with obesity disease and either a BMI \u226535 kg\/m2 with at least 1 obesity-related comorbidity (hypertension, dyslipidemia, or type 2 diabetes), or a BMI \u226527 kg\/m\u00b2 with at least 2 obesity-related health disorders, were included. The intervention was semaglutide 2.4 mg plus diet and exercise vs diet and exercise alone. We modeled retreatment scenarios (0, 1, or 2 retreatments) with a fixed 1-year off-treatment period after each regimen. Complication costs were sourced from Japanese studies. The primary outcome was the incremental cost-effectiveness ratio (ICER) in Japanese yen per quality adjusted life year (QALY), discounted at 2%.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In the base case, semaglutide 2.4 mg reduced the incidence of obesity-related complications, such as type 2 diabetes (T2D), cardiovascular events, obstructive sleep apnea, and gout. The ICER was \u00a55\u2009300\u2009580\/QALY for patients with obesity disease without T2D, and \u00a57\u2009077\u2009984\/QALY for patients with obesity disease with T2D. Retreatment significantly improved QALY gains compared with limited or no retreatment, reflecting longer maintenance of treatment benefit.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Accounting for OUG consistent retreatment in Japan improved the cost-effectiveness of semaglutide 2.4 mg and provided a more realistic representation of long-term obesity management than single course assumptions. Analyses that omit retreatment may underestimate its long-term value in Japanese clinical practice. Results were broadly robust, although uncertainty remains around retreatment efficacy and long-term discontinuation. Semaglutide 2.4 mg represents a clinically and economically valuable intervention for obesity disease in Japan. These findings emphasize the need for long\u2011term, clinically realistic assessments when evaluating obesity treatments in Japan.<\/jats:p>\n <\/jats:sec>","DOI":"10.36469\/001c.162614","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:05:31Z","timestamp":1782849931000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios"],"prefix":"10.36469","volume":"13","author":[{"given":"Yuta","family":"Kamada","sequence":"first","affiliation":[{"name":"Novo Nordisk Pharma Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Wada","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharma Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2589-9288","authenticated-orcid":false,"given":"Hiroyuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Japan G.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Dai","sequence":"additional","affiliation":[{"name":"IQVIA Solutions Japan G.K., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref1","article-title":"Cost-effectiveness evaluation of semaglutide for overweight and obesity","author":"Y. Akune"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"P. J. Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ref3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/osp4.495","article-title":"A novel decision model to predict the impact of weight management interventions: the Core Obesity Model","volume":"7","author":"S. Lopes","year":"2021","journal-title":"Obes Sci Pract"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"e000302","DOI":"10.1136\/bmjph-2023-000302","article-title":"Assessing the health and economic burden of obesity-related complications in East-Asian populations: implementation of risk equations in the Core Obesity Model for Japan and model validation","volume":"2","author":"I. Tatsuno","year":"2024","journal-title":"BMJ Public Health"},{"key":"ref5","article-title":"Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council 2024","author":"Center for Outcomes Research and Economic Evaluation for Health","year":"2024"},{"issue":"3","key":"ref6","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s12325-022-02423-8","article-title":"Once-weekly subcutaneous semaglutide 2.4 mg injection is cost-effective for weight management in the United Kingdom","volume":"40","author":"H. Sandhu","year":"2023","journal-title":"Adv Ther"},{"issue":"8","key":"ref7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"J. P. H. Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"ref8","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta16050","article-title":"What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review","volume":"16","author":"R. Ara","year":"2012","journal-title":"Health Technol Assess"},{"issue":"10","key":"ref9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"P. Clarke","year":"2004","journal-title":"Diabetologia"},{"issue":"6","key":"ref10","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/dom.15546","article-title":"The association between body mass index and health-related quality of life in the 2017 and 2018 health survey of England data: a cross-sectional observational analysis","volume":"26","author":"X. W. Luah","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"ref11","article-title":"Clinical Problems Caused by Obesity","author":"I. Kyrou","year":"2018"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12913-024-11474-2","article-title":"No medication prescription and residential distance from the hospital are important factors associated with nonsurgical weight-loss treatment discontinuance in Japanese patients with high-degree obesity: a retrospective study","volume":"24","author":"M. Ohira","year":"2024","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11030231","article-title":"The epidemiology and genetics of hyperuricemia and gout across major racial groups: a literature review and population genetics secondary database analysis","volume":"11","author":"F. Butler","year":"2021","journal-title":"J Pers Med"},{"issue":"7","key":"ref14","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.2337\/dc06-0057","article-title":"Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study","volume":"29","author":"I. Shai","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"ref15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1017\/S1368980008002802","article-title":"Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians","volume":"12","author":"C.P. Wen","year":"2009","journal-title":"Public Health Nutr"},{"key":"ref16","article-title":"Tirzepatide for managing overweight and obesity. Technology appraisal guidance TA1026","author":"National Institute for Health and Care Excellence"},{"issue":"7","key":"ref17","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2025.1159","article-title":"Reimbursement Recommendations Semaglutide (Wegovy)","volume":"5","author":"Canada Drug Agency","year":"2025","journal-title":"Can J Health Technol"},{"key":"ref18","article-title":"Semaglutide for managing overweight and obesity TA875","author":"National Institute for Health and Care Excellence"},{"key":"ref19","article-title":"WEGOVY (s\u00e9maglutide) - Ob\u00e9sit\u00e9","author":"HAUTE AUTORITE DE SANTE"},{"issue":"4","key":"ref20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","article-title":"The history and future of the \"ISPOR Value Flower\": addressing limitations of conventional cost-effectiveness analysis","volume":"25","author":"P. J. Neumann","year":"2022","journal-title":"Value Health"},{"key":"ref21","article-title":"Guidelines for the Management of Obesity Disease 2022","author":"Japan Society for the Study of Obesity","year":"2022"},{"key":"ref22","article-title":"National Health and Nutrition Survey (NHNS): BMI distribution table (obesity BMI\u226525; BMI\u226530)","author":"Ministry of Health, Labour and Welfare"},{"issue":"3","key":"ref23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1507\/endocrj.EJ23-0416","article-title":"The humanistic and societal impact of obesity in Japan: a targeted literature review","volume":"71","author":"W. Ogawa","year":"2024","journal-title":"Endocr J"},{"issue":"4","key":"ref24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41366-024-01694-1","article-title":"BMI trajectory of 8,155,894 Japanese adults from exhaustive health checkup data: the contributions of age-related changes in height and weight","volume":"49","author":"N. Uemura","year":"2025","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"ref25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.36469\/001c.123991","article-title":"Assessing the fiscal burden of overweight and obesity in Japan through application of a public economic framework","volume":"11","author":"A. Igarashi","year":"2024","journal-title":"J Health Econ Outcomes Res"},{"issue":"3","key":"ref26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1507\/endocrj.EJ23-0593","article-title":"Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan","volume":"71","author":"W. Ogawa","year":"2024","journal-title":"Endocr J"},{"issue":"3","key":"ref27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"T. Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref28","article-title":"Optimal Use Promotion Guideline semaglutide","author":"Ministry of Health, Labor and Welfare"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/162614-cost-effectiveness-of-semaglutide-2-4-mg-for-obesity-disease-management-in-japan-a-lifetime-economic-modeling-study-incorporating-retreatment-scenari","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:05:33Z","timestamp":1782849933000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/162614-cost-effectiveness-of-semaglutide-2-4-mg-for-obesity-disease-management-in-japan-a-lifetime-economic-modeling-study-incorporating-retreatment-scenari"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.162614","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}